Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$15.59
+1.4%
$12.26
$6.38
$16.66
$1.49B1.581.37 million shs1.37 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$25.09
-4.4%
$31.29
$24.28
$55.33
$1.58B2.311.49 million shs1.71 million shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$25.08
+1.3%
$22.25
$18.53
$51.61
$1.58B1.171.87 million shs2.22 million shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$8.58
-0.1%
$6.58
$3.55
$16.11
$390.31M0.53953,183 shs298,459 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
+1.37%+4.07%+22.27%+57.63%+9.48%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-4.42%-4.38%-2.15%-28.62%-32.66%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
+1.33%+10.92%+26.73%+13.48%-34.50%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-0.12%+0.23%+0.82%+74.04%-35.83%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$15.59
+1.4%
$12.26
$6.38
$16.66
$1.49B1.581.37 million shs1.37 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$25.09
-4.4%
$31.29
$24.28
$55.33
$1.58B2.311.49 million shs1.71 million shs
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
$25.08
+1.3%
$22.25
$18.53
$51.61
$1.58B1.171.87 million shs2.22 million shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$8.58
-0.1%
$6.58
$3.55
$16.11
$390.31M0.53953,183 shs298,459 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
+1.37%+4.07%+22.27%+57.63%+9.48%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-4.42%-4.38%-2.15%-28.62%-32.66%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
+1.33%+10.92%+26.73%+13.48%-34.50%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-0.12%+0.23%+0.82%+74.04%-35.83%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
3.11
Buy$20.8633.79% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4096.89% Upside
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
2.90
Moderate Buy$63.00151.20% Upside
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
1.80
Reduce$9.6212.15% Upside

Current Analyst Ratings Breakdown

Latest YMAB, TWST, VERA, and AVDL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/5/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$24.00 ➝ $36.00
9/3/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
9/3/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/2/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageEqual Weight$16.00
8/21/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$13.00 ➝ $20.00
8/8/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/8/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/8/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$22.00 ➝ $24.00
8/7/2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$56.00 ➝ $53.00
8/6/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyNeutral$11.00 ➝ $8.60
8/5/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$8.60
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$169.12M8.95N/AN/A$0.77 per share20.25
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$362.27M4.18N/AN/A$8.07 per share3.11
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/A$9.08 per shareN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$85.39M4.57N/AN/A$2.05 per share4.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$48.83M-$0.03N/A259.83N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%11/17/2025 (Estimated)
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$152.15M-$3.58N/AN/AN/AN/A-46.70%-39.46%11/6/2025 (Estimated)
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$29.67M-$0.50N/AN/AN/A-26.03%-24.60%-18.89%11/14/2025 (Estimated)

Latest YMAB, TWST, VERA, and AVDL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.27-$0.07+$0.20-$0.07$18.40 million$19.52 million
8/7/2025Q2 2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$0.02$0.10+$0.08$0.10$60.28 million$68.13 million
8/5/2025Q2 2025
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
-$0.82-$1.20-$0.38-$1.20N/AN/A
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/A
2.79
2.38
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
3.60
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
0.16
17.03
17.03
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
4.00
3.58

Institutional Ownership

CompanyInstitutional Ownership
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
69.19%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
99.21%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
5.20%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
16.30%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
19.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
7097.10 million92.05 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable
Vera Therapeutics, Inc. stock logo
VERA
Vera Therapeutics
4063.82 million53.42 millionOptionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.44 million36.49 millionOptionable

Recent News About These Companies

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update
Y-mAbs (YMAB) Q2 Revenue Falls 14%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Avadel Pharmaceuticals stock logo

Avadel Pharmaceuticals NASDAQ:AVDL

$15.59 +0.21 (+1.37%)
Closing price 09/9/2025 04:00 PM Eastern
Extended Trading
$15.67 +0.08 (+0.51%)
As of 09/9/2025 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$25.09 -1.16 (-4.42%)
Closing price 09/9/2025 04:00 PM Eastern
Extended Trading
$25.24 +0.15 (+0.60%)
As of 09/9/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Vera Therapeutics stock logo

Vera Therapeutics NASDAQ:VERA

$25.08 +0.33 (+1.33%)
Closing price 09/9/2025 04:00 PM Eastern
Extended Trading
$24.42 -0.65 (-2.61%)
As of 09/9/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

$8.58 -0.01 (-0.12%)
Closing price 09/9/2025 04:00 PM Eastern
Extended Trading
$8.58 0.00 (0.00%)
As of 09/9/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.